Research and trials

Cancer Research UK is collaborating with Aleta Therapeutics (Aleta) to trial a new therapy that ‘reboots’ a treatment for some people with blood cancer whose cancer starts to come back.

Cancer Research UK’s spin-out, GammaDelta Therapeutics, has been given approval to trial its unique T-cell therapy in the US.  

The first participants have taken part in a new research trial that aims to save lives by detecting lung cancer at an earlier stage when it is more treatable.

Around 10,600 fewer breast cancer patients have started treatment in the last year in England, as experts fear hard-won progress could slow.

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.

The director of our Cancer Research UK Edinburgh Centre walks us through some of his proudest research achievements and how supporters have made them possible.

Teasing apart causation from correlation is vital if we are to understand whether the gut microbiome changes the risk of cancer or whether cancer changes the gut microbiome

Widely-used anti-inflammatory drugs make tumours in mice more responsive to treatments that harness the power of the body’s own immune system to tackle cancer, according to research funded by Cancer Research UK and published in the journal Cancer Discovery.

The new findings shed light on how cancer cells found in different parts of a tumour behave differently.

Cancer Research UK’s spinout, Achilles Therapeutics plc (‘Achilles’), has raised $175.5 million through the closing of its initial public offering (IPO).